Bicalutamide and Ridaforolimus in Men With Prostate Cancer (MK-8669-002)
NCT00777959
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
22
Enrollment
INDUSTRY
Sponsor class
Conditions
Prostate Cancer
Interventions
DRUG:
ridaforolimus (MK8669)
DRUG:
Comparator: Placebo
DRUG:
open-label ridaforolimus (MK8669)
Sponsor
Merck Sharp & Dohme LLC
Collaborators
[object Object]